T1	Participants 50 79	chronic lymphocytic leukemia.
T2	Participants 195 229	chronic lymphocytic leukemia (CLL)
T3	Participants 414 479	300 pretreatment specimens from a subset of 552 patients in REACH
T4	Participants 1317 1329	CLL patients
